Clioquinol - Gerolymatos Group/Prana Biotechnology

Drug Profile

Clioquinol - Gerolymatos Group/Prana Biotechnology

Alternative Names: Chloroiodoquine; Gero-46; Iodochlorhydroxyquin; Iodochlorhydroxyquinoline; PBT-1

Latest Information Update: 13 Apr 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gerolymatos Group; Prana Biotechnology
  • Class Antibacterials; Antidementias; Antifungals; Antiprotozoals; Hydroxyquinolines; Ionophores; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 11 Apr 2005 Discontinued - Phase-II for Alzheimer's disease in Australia (unspecified route)
  • 04 Jan 2005 Prana Biotechnology has received a CTA from the UK MHRA to initiate a phase II/III trial
  • 19 Apr 2004 Data from a media release have been added to the Alzheimer's disease therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top